Skip to main content

CMSC 2025 | May 28, 2025 - May 31, 2025

Neurology

Using cutting-edge technologies, Sanofi scientists are developing targeted, potentially disease-modifying therapies for people living with multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chronic inflammatory demyelinating polyneuropathy (CIDP), and other chronic, debilitating neurological disorders. Our goal is to design best-in-class medicines that slow or halt neurodegeneration, control neuroinflammation, and protect or even repair the nervous system.

Available rooms
1 of 1
  • Tolebrutinib in MS

    Multiple sclerosis (MS) is an autoimmune disorder that causes neuroinflammation in the brain and spinal cord. The resulting lesions can either shrink or remain "chronically active" over the course of years, leading to accelerated loss of brain volume. This leads to unpredictable symptoms, such as vision problems, challenges with cognition, and difficulty with physical activity.

  • Frexalimab in MS

    Multiple sclerosis (MS) is an autoimmune disorder that causes neuroinflammation in the brain and spinal cord. The resulting lesions can either shrink or remain "chronically active" over the course of years, leading to accelerated loss of brain volume. This leads to unpredictable symptoms, such as vision problems, challenges with cognition, and difficulty with physical activity.

  • Multiple sclerosis

    Multiple sclerosis (MS) is an autoimmune disorder that causes neuroinflammation in the brain and spinal cord. The resulting lesions can either shrink or remain "chronically active" over the course of years, leading to accelerated loss of brain volume. This leads to unpredictable symptoms, such as vision problems, challenges with cognition, and difficulty with physical activity.